Evaluation of the in vitro activity of ceftaroline and comparators against S. pneumoniae isolates from U.S. hospitals: Results from 7 years of the AWARE Surveillance Program (2010-2016) [PublishAheadOfPrint]

We evaluated trends in Streptococcus pneumoniae antimicrobial susceptibility in United States hospitals in the 2010--2016 period. A total of 8,768 clinical isolates from 47 medical centers were tested for susceptibility by broth microdilution methods. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) rates decreased from 25.7/12.4% (MDR/XDR) in 2010 to 17.7%/3.6% in 2016. Susceptibility to most comparator antimicrobial agents increased, whereas susceptibility to ceftaroline, levofloxacin, linezolid, and tigecycline remained stable. Ceftaroline retained potent activity against S. pneumoniae (>99.9%) with no marked variations.

http://ift.tt/2zW916Q